Fate Therapeutics (FATE) Projected to Release Earnings on Tuesday

Fate Therapeutics (NASDAQ:FATE) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.28) per share and revenue of $1.3740 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.49 million. Fate Therapeutics had a negative return on equity of 58.89% and a negative net margin of 2,056.79%. On average, analysts expect Fate Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fate Therapeutics Price Performance

Shares of Fate Therapeutics stock traded down $0.04 during midday trading on Tuesday, hitting $2.46. The company had a trading volume of 538,667 shares, compared to its average volume of 2,642,688. The stock has a market cap of $287.32 million, a PE ratio of -2.26 and a beta of 2.52. The business’s 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $1.77. Fate Therapeutics has a 1-year low of $0.91 and a 1-year high of $3.23.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on FATE. Weiss Ratings raised Fate Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research note on Monday, June 8th. Finally, Jefferies Financial Group set a $4.00 target price on shares of Fate Therapeutics in a research note on Tuesday, May 19th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.12.

Insider Activity

In other Fate Therapeutics news, insider Cindy Tahl sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.88, for a total value of $48,109.20. Following the sale, the insider owned 628,155 shares in the company, valued at approximately $1,180,931.40. The trade was a 3.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On Fate Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in FATE. Vanguard Group Inc. boosted its position in Fate Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 8,798,491 shares of the biopharmaceutical company’s stock valued at $11,086,000 after purchasing an additional 31,727 shares during the last quarter. Geode Capital Management LLC grew its holdings in Fate Therapeutics by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,429,167 shares of the biopharmaceutical company’s stock valued at $2,721,000 after buying an additional 159,558 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Fate Therapeutics by 87.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,360,881 shares of the biopharmaceutical company’s stock worth $2,320,000 after purchasing an additional 1,098,366 shares during the period. AQR Capital Management LLC increased its position in shares of Fate Therapeutics by 2.7% in the fourth quarter. AQR Capital Management LLC now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $1,142,000 after purchasing an additional 30,591 shares during the period. Finally, Millennium Management LLC raised its position in Fate Therapeutics by 9.6% during the third quarter. Millennium Management LLC now owns 963,871 shares of the biopharmaceutical company’s stock valued at $1,214,000 after purchasing an additional 84,183 shares in the last quarter. 97.54% of the stock is owned by institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.